SFM
FLAC

Spartan Fund Management’s Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares FLAC Stock Holding History

Spartan Fund Management’s Portfolio FLAC Stock Details FLAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-240,000
Closed -$2.37M – 540
2022
Q2 		$2.37M Hold
240,000
– – 0.5% 46
2022
Q1 		$2.95M Buy
+240,000
New +$2.35M 0.48% 51

Other funds holding FLAC

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
MA
MYDA Advisors Woodmere, New York $672M AUM 71.14% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
GL
Governors Lane New York $1.2B AUM 26.21% 1-Year Est. Return

Spartan Fund Management's FLAC Position: Q3 2022 in Review

Spartan Fund Management sold out of Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares (FLAC) in Q3 2022, closing a stake of 240,000 shares — an estimated $2.37M sold.

Spartan Fund Management first reported a position in FLAC in Q1 2022 and held it in 2 quarters. The position peaked at $2.95M in Q1 2022. 52 funds tracked by Wall St. Rank hold FLAC as of Q3 2022.

  • Spartan Fund Management reported no remaining Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares position as of Q3 2022 after selling out during the quarter.
  • Spartan Fund Management sold 240,000 Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares shares in Q3 2022, an estimated $2.37M.
  • Spartan Fund Management first reported a position in Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares in Q1 2022 and held it in 2 quarters.
  • Spartan Fund Management's Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares position peaked at $2.95M in Q1 2022.
  • 52 funds tracked by Wall St. Rank held Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares as of Q3 2022.

Based on Spartan Fund Management's 13F filing for Q3 2022, filed 26 Oct 2022.